SynthesisAnnals of the rheumatic diseases2019
Consensus-based recommendations for the management of juvenile localised scleroderma.
Synthesis in Annals of the rheumatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 131 citations in OpenAlex.
- Article
- Under the Surface: A Rare Case of the En Coup De Sabre Subtype of Linear Morphea in the Rio Grande Valley.Cureus · 2026Article
- Parry-Romberg Syndrome: Radioclinical Dissociation in a Paucisymptomatic Form and a Proposed Diagnostic Framework.Diagnostics (Basel, Switzerland) · 2026Article
- Intravenous immunoglobulin for the treatment of morphea in pediatric patients: A case series.JAAD case reports · 2026Article
- [Noninfectious uveitis in childhood : Clinical aspects, diagnostics, treatment and transition].Die Ophthalmologie · 2026Review
- Review
- JAK inhibitors for the treatment of juvenile localized scleroderma: a case report and literature review.Pediatric rheumatology online journal · 2026Review
- Tofacitinib treatment in a girl with localized scleroderma of the head and face: a case-based review.Rheumatology international · 2026Review
- Successful tocilizumab-based combination therapy for a case of rapidly progressive adult deep morphea with multiple antiphospholipid antibodies: a case report and literature review.Frontiers in immunology · 2026Review
- The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care.Rheumatology (Oxford, England) · 2025Review
- Article
- Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center.Pediatric rheumatology online journal · 2025Article
- Development of Coup de Sabre in an HIV-Positive Patient: A Case Study from Lilongwe, Malawi.The American journal of tropical medicine and hygiene · 2025Article
- Markers of Type 2 Inflammation and Immunosenescence Are Upregulated in Localized Scleroderma.International journal of molecular sciences · 2025Article
- What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.Journal of clinical medicine · 2024Review
- Juvenile Scleroderma.Indian journal of pediatrics · 2024Review
- Article
- Biomarkers in skin autoimmunity-An update on localised scleroderma.Skin health and disease · 2024Review
- [Juvenile localized scleroderma].Dermatologie (Heidelberg, Germany) · 2024Review
- Damage evaluation of craniofacial localized scleroderma using magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 14 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2012, a European initiative called Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile localised scleroderma (JLS) is a rare disease within the group of paediatric rheumatic diseases (PRD) and can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. This study aims to provide recommendations for assessment and treatment of JLS. Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was formed, mainly from Europe, and consisted of 15 experienced paediatric rheumatologists and two young fellows. Recommendations derived from a validated systematic literature review were evaluated by an online survey and subsequently discussed at two consensus meetings using a nominal group technique. Recommendations were accepted if ≥80% agreement was reached. In total, 1 overarching principle, 10 recommendations on assessment and 6 recommendations on therapy were accepted with ≥80% agreement among experts. Topics covered include assessment of skin and extracutaneous involvement and suggested treatment pathways. The SHARE initiative aims to identify best practices for treatment of patients suffering from PRDs. Within this remit, recommendations for the assessment and treatment of JLS have been formulated by an evidence-informed consensus process to produce a standard of care for patients with JLS throughout Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.